Telepathic Technologies

Market position

Telepathic operates in the non-invasive segment of the brain-computer interface market, which sources divide into invasive approaches (exemplified by Neuralink's implanted sensor) and non-invasive approaches such as Telepathic's fNIRS cap. Coverage frames the company within a geopolitical competition narrative, noting that China accounts for over 35% of worldwide patent submissions for non-implantable acquisition and sensing technology.

Sources contrast Telepathic's approach with invasive BCIs such as Neuralink's implanted N1 sensor and neural threads: because the fNIRS cap requires no surgery, it is presented as accessible to a wider market. Additional stated design choices include constraining the decoding problem to the 26-word NATO phonetic alphabet rather than the full English alphabet, and building per-user calibrated models to account for individual signal variation.

Technology

Functional near-infrared spectroscopy (fNIRS) is the core sensing modality, measuring changes in blood oxygen levels via near-infrared light to monitor brain activity. Hardware takes the form of a scalp-worn cap with multiple optodes wired to a connector feeding recording equipment. Machine-learning models decode the acquired signals into intended words; the company builds individual per-user models because calibration is highly personalised. The website additionally describes a real-time signal acquisition and interpretation engine providing insights into cognitive states, and secure transmission of thought and intent between human and machine.

Go-to-market

The company website runs a public waitlist for beta testers. Published coverage frames the go-to-market as defense-focused, targeting U.S. warfighters and positioning the product as a drop-in replacement for the microphone within existing headset and helmet systems.

Defense and military personnel, specifically U.S. warfighters needing communication in silence-critical environments. Earlier testing involved stroke patients, and the founders have described potential dual-use expansion, including VR/XR.

Geography

Sources place the team in San Francisco as of June 2024, with the target market described as the U.S. defense sector.

History

Founders Noah Shamus and Ellery Buntel both attended Tufts University — Shamus as an undergraduate and Buntel for PhD study — and Buntel left his PhD program to co-found the company. The founders initially tested the technology with stroke patients before shifting toward defense applications, a pivot described as inspired by military strategist John Boyd's emphasis on the individual warfighter over the machine. As of June 2024 the team was reported to be based in San Francisco and raising a pre-seed round. The company website lists Jason Rosenstein as a strategic investor.

Risks & controversies

Reported technical risks include signal quality: fNIRS optode contact is sensitive to factors such as perspiration, which introduces noise and degrades data quality for the machine-learning models, and calibration is highly personalised, requiring individual models per user. Decoding accuracy was reported at 76% on only a subset of the NATO phonetic alphabet. Note that at least one aggregator page indexed under the name 'Telepathic' contains materially conflicting and unverifiable claims (a 2014 founding date, $14.8M across five rounds, different named founders, large Series A and FDA milestones); those claims are not corroborated by the company's own site or by the profile coverage and have not been recorded here.